Artesunate, Imatinib, and Infliximab in Covid-19: A Rapid Review and Meta-Analysis of Current Evidence Publisher Pubmed



Amani B¹ ; Zareei S² ; Amani B¹ ; Zareei M³ ; Zareei N⁴ ; Shabestan R⁵ ; Akbarzadeh A⁵
Source: Immunity# Inflammation and Disease Published:2022

Abstract

Background and Objective: Despite the pervasive vaccination program against coronavirus disease 2019 (COVID-19), fully vaccinated people are still being infected by severe acute respiratory syndrome coronavirus 2, making an effective and safe therapeutic intervention a crucial need for the patients' survival. The purpose of the present study is to seek available evidence for the efficacy and safety of three promising medications artesunate, imatinib, and infliximab against COVID-19. Methods: A literature search was conducted in PubMed, Cochrane Library, medRxive, and Google Scholar up to January 2022. Furthermore, the clinical trial databases were screened to find more citations. The Cochrane Collaboration tool and Newcastle–Ottawa scale were used to assess the included studies. Meta-analysis was performed using RevMan 5.4.1. Results: Five published studies were identified as eligible. Meta-analysis showed that there was no significant difference between the infliximab and control groups in terms of mortality rate (risk ratio [RR]: 0.65; 95% confidence interval [CI]: 0.40–1.07; p = 0.09). However, a significant difference was observed between the two groups for the hospital discharge (RR: 1.37; 95% CI: 1.04–1.80; p = 0.03). No remarkable clinical benefit was observed in favor of using imatinib for COVID-19 patients. Artesunate showed significant improvement in patients with COVID-19. Conclusion: In the present, limited evidence exists for the efficacy and safety of artesunate, imatinib, and infliximab in patients with COVID-19. The findings of WHO's Solidarity international trial will provide further information regarding these therapeutic interventions. © 2022 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.